SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF) , 前瞻盈利收益率 43.86%. PEG 0.06 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
- 前瞻市盈率 2.3
- PEG 比率 0.06 — 低于1.0表明股票相对于其盈利增长率被低估（Peter Lynch 标准）。
SharesGrow 综合评分： 33/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
~
健康
67/100
Debt-to-Equity & liquidity
→ Health
估值概览 — SHPHF
估值倍数
P/E (TTM)0.0
前瞻 P/E2.3
PEG 比率0.06
前瞻 PEG0.06
P/B 比率0.00
P/S 比率0.91
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.02
前瞻 EPS（预估）$0.08
每股账面价值$0.00
每股营收$0.21
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield43.86%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2015 |
$0.20 |
$3.17B |
$2.06B |
65.1% |
| 2016 |
$0.17 |
$3.19B |
$1.71B |
53.6% |
| 2017 |
$0.15 |
$2.75B |
$1.45B |
52.8% |
| 2018 |
$0.17 |
$2.92B |
$1.62B |
55.5% |
| 2019 |
$-0.29 |
$2.88B |
$-2.71B |
-94.1% |
| 2020 |
$0.05 |
$2.46B |
$473.38M |
19.2% |
| 2021 |
$0.05 |
$3.04B |
$416.51M |
13.7% |
| 2022 |
$-0.21 |
$2.18B |
$-1.95B |
-89.5% |
| 2023 |
$-0.01 |
$1.86B |
$-54.02M |
-2.9% |
| 2024 |
$-0.02 |
$1.9B |
$-216.66M |
-11.4% |
